A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infectionJOURNAL OF MEDICAL VIROLOGYIF4.62022-09-122OAAI
Mechanisms of Musculoskeletal Frailty in People Living with HIVJOURNAL OF FRAILTY & AGINGIF3.32022-01-010PRE
Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV InfectionFRONTIERS IN IMMUNOLOGYIF5.92019-06-2712OAAI
The Induction of Autoimmune Arthritis and Sex Differences in Mice Impact the Lung Inflammatory Response to Repetitive Inhalant Organic Dust Extract ExposuresJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22019-02-010OAAI
Implementation of a unique hepatitis C care continuum model in RwandaJOURNAL OF PUBLIC HEALTHIF3.12018-07-063PREAI
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvirAIDSIF3.12016-01-0123OAAI
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 InfectionANNALS OF INTERNAL MEDICINEIF15.22015-12-1552OAAI
High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a studyHEPATOLOGY INTERNATIONALIF6.12015-11-2655OAAI
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensCLINICAL INFECTIOUS DISEASESIF7.32015-10-3144OAAI
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseCLINICAL INFECTIOUS DISEASESIF7.32015-10-2628OA
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyLANCET INFECTIOUS DISEASESIF312015-09-01125OAAI
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infectionJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552015-03-24174OAAI
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy丙型肝炎病毒载量监测对直接作用抗病毒治疗的效用CLINICAL INFECTIOUS DISEASESIF7.32015-03-0281OAAI
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyLANCETIF88.52015-03-01129OAAI
Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse An Open-Label Pilot StudyANNALS OF INTERNAL MEDICINEIF15.22014-11-0458OAAI
Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis CHEPATOLOGY INTERNATIONALIF6.12014-09-2111PREAI
Clinical presentation of children with pulmonary tuberculosis: 25 years of experience in Lima, PeruINTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASEIF3.12014-09-019PREAI
Abnormal B cell memory subsets dominate HIV-specific responses in infected individualsJOURNAL OF CLINICAL INVESTIGATIONIF13.62014-06-02124OAAI
CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammationJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22014-06-0121OAAI
RETREATMENT OF RELAPSERS TO SOFOSBUVIR/RIBAVIRIN WITH SOFOSBUVIR/LEDIPASVIR: COMPLETE AND RAPID VIROLOGIC SUPPRESSION BY WEEK 4JOURNAL OF HEPATOLOGYIF332014-04-016PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向